IDERA PHARMACEUTICALS INC (IDRA)
US45168K4058 - Common Stock
IDERA PHARMACEUTICALS INC
NASDAQ:IDRA (1/17/2023, 7:00:02 PM)
After market: 0.42 -0.01 (-1.18%)0.425
-0.12 (-21.57%)
Company Profile
Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company is headquartered in Exton, Pennsylvania and currently employs 13 full-time employees. The firm is developing tilsotolimod, an investigational Toll-like receptor 9 agonist, for the treatment of advanced solid tumors. Its lead investigational product, tilsotolimod, demonstrated activity in various pre-clinical models and is in clinical development across several oncology indications. These indications include anti-PD-1 refractory advanced melanoma, microsatellite-stable colorectal cancer (MSS-CRC, phase II), and recurrent/metastatic head & neck squamous cell carcinoma (HNSCC, phase I/II). Tilsotolimod is used for the treatment of anti-PD-1 refractory melanoma, in combination with ipilimumab, as well as for the treatment of stage IIb-IV melanoma. Its clinical trials include ILLUMINATE-204, ILLUMINATE-206 and ILLUMINATE-101. The company is also focused on rare, orphan pulmonary and rheumatic diseases.
Company Info
IDERA PHARMACEUTICALS INC
505 Eagleview Boulevard, Suite 212
Exton PENNSYLVANIA 19341
P: 14843481600.0
CEO: Vincent J. Milano
Employees: 13
Website: http://www.iderapharma.com/
IDRA News
a year ago - Seeking AlphaIDRA stock slips ahead of reverse stock split (NASDAQ:IDRA)Idera Pharmaceuticals (IDRA) fell ~22% Tuesday after the company said that a 1-for-17 reverse stock split of common stock would take effect tomorrow at the open. Read the full story here.
Acquisition includes late-stage rare disease portfolio with anticipated 2023 clinical milestones and first potential product approval as early as late 2024...
EXTON, Pa., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported...
2 years ago - InvestorPlaceToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayGood morning, trader! We're starting off the week with an overview of the biggest pre-market stock movers for Monday morning!
– Enrollment Stopped Early for Efficacy –...
EXTON, Pa., May 05, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its...
IDRA Twits
Here you can normally see the latest stock twits on IDRA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
